TRIM24 and breast carcinoma: Eight (11%, 2 in Cluster 1, 6 in Cluster 2) patients developed a malignancy (3 myeloproliferative disorders, one lymphoma, one breast cancer, one ovarian cancer, one bronchial cancer and one thyroid cancer), including one of the three patients who exhibited anti-TIF1-γ antibodies.